Roan Capital Partners’s AbbVie ABBV Stock Holding History

Roan Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$542K	Sell	2,152 -117	-5%	-$25.2K	0.45%	45
2026 Q1	$493K	Buy	+2,269	New	+$503K	0.46%	39

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Roan Capital Partners's ABBV Position: Q2 2026 in Review

Roan Capital Partners reduced its AbbVie (ABBV) stake by 5.2% in Q2 2026, selling an estimated $25.2K and leaving 2,152 shares worth $542K. The position accounts for 0.45% of the portfolio, ranked #45.

Roan Capital Partners first reported a position in ABBV in Q1 2026 and has held it in 2 quarters since. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Roan Capital Partners held 2,152 shares of AbbVie worth $542K as of Q2 2026.
Roan Capital Partners sold 117 AbbVie shares in Q2 2026, an estimated $25.2K.
AbbVie made up 0.45% of Roan Capital Partners's portfolio in Q2 2026, its #45 holding.
Roan Capital Partners first reported a position in AbbVie in Q1 2026 and has held it in 2 quarters since.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Roan Capital Partners's 13F filing for Q2 2026, filed 9 Jul 2026.